Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005;7(1-2):79-99.
doi: 10.1385/NMM:7:1-2:079.

Protease-activated receptors: regulation of neuronal function

Affiliations
Review

Protease-activated receptors: regulation of neuronal function

Toshiyuki Saito et al. Neuromolecular Med. 2005.

Abstract

Certain serine proteases from the circulation (e.g., coagulation factors), inflammatory cells (e.g., mast-cell tryptase, neutrophil proteinase 3), and from many other cell types (e.g., trypsins) can specifically signal to cells by cleaving protease-activated receptors (PARs), a family of four G protein-coupled receptors. Proteases cleave PARs at specific sites within the extracellular amino-terminus to expose amino-terminal tethered ligand domains that bind to and activate the cleaved receptors. The proteases that activate PARs are often generated and released during injury and inflammation, and activated PARs orchestrate tissue responses to injury, including hemostasis, inflammation, pain, and repair. This review concerns protease and PAR signaling in the nervous system. Neurons of the central and peripheral nervous systems express all four PARs. Proteases that may derive from the circulation, inflammatory cells, or neural tissues can cleave PARs on neurons and thereby activate diverse signaling pathways that control survival, morphology, release of neurotransmitters, and activity of ion channels. In this manner proteases and PARs regulate neurodegeneration, neurogenic inflammation, and pain transmission. Thus, PARs may participate in disease states and PAR antagonists or agonists may be useful therapies for certain disorders.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neuroreport. 2004 Jul 19;15(10):1617-21 - PubMed
    1. Am J Pathol. 2001 Feb;158(2):681-90 - PubMed
    1. J Neurochem. 2000 Apr;74(4):1731-8 - PubMed
    1. Nature. 1997 Apr 3;386(6624):502-6 - PubMed
    1. J Neurosci. 2004 May 5;24(18):4293-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources